Unknown

Dataset Information

0

Development of ZD2767P-carboxypeptidase G2-ultrasound therapy against cisplatin-resistant cancer.

ABSTRACT:

SUBMITTER: Yu T 

PROVIDER: S-EPMC10233003 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Development of ZD2767P-carboxypeptidase G2-ultrasound therapy against cisplatin-resistant cancer.

Yu Tinghe T   Li Xinya X  

Frontiers in oncology 20230518

Similar Datasets

Unknown Ultrasonically Enhanced ZD2767P-Carboxypeptidase G2 Deactivates Cisplatin-Resistant Human Lung Cancer Cells.
| S-EPMC9652066 | biostudies-literature
Unknown Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells
| S-EPMC12335911 | biostudies-literature
Unknown Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin.
| S-EPMC10196713 | biostudies-literature
Unknown Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center.
| S-EPMC10660123 | biostudies-literature
Unknown Intermittent fasting enhances cisplatin-metformin efficacy in therapy-resistant ovarian cancer PDXs.
| S-EPMC12803865 | biostudies-literature
Unknown Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.
| S-EPMC11312340 | biostudies-literature
Unknown Engineering carboxypeptidase G2 circular permutations for the design of an autoinhibited enzyme.
| S-EPMC6283397 | biostudies-literature
Unknown Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation Therapy.
| S-EPMC11406688 | biostudies-literature
Unknown Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.
| S-EPMC9785832 | biostudies-literature
Unknown Nanoparticle-assisted ultrasound: A special focus on sonodynamic therapy against cancer.
| S-EPMC6420022 | biostudies-literature